UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 110

Sortiert nach

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older

The New England journal of medicine, 2017-06, Vol.376 (25), p.2427-2436

2017

Volltextzugriff (PDF)

Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE + GLA) adjuvant

Vaccine, 2013-11, Vol.31 (48), p.5760-5765

2013

Volltextzugriff (PDF)

Recombinant hemagglutinin influenza vaccine provides broader spectrum protection

Expert review of vaccines, 2016-08, Vol.15 (8), p.957-966

2016

Volltextzugriff (PDF)

NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial

Vaccine, 2023-05, Vol.41 (22), p.3461-3466

2023

Volltextzugriff (PDF)

Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults

Vaccine, 2023-09, Vol.41 (41), p.5965-5973

2023

Volltextzugriff (PDF)

Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine

Expert review of vaccines, 2023-12, Vol.22 (1), p.501-517

2023

Volltextzugriff (PDF)

Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18–49 Years of Age

The Journal of infectious diseases, 2017-12, Vol.216 (10), p.1219-1226

2017

Volltextzugriff (PDF)

Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized Trial

Pediatrics (Evanston), 2018-05, Vol.141 (5)

2018

Volltextzugriff (PDF)

Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines

The Journal of infection, 2024-03, Vol.88 (3), p.106119-106119, Article 106119

2024

Volltextzugriff (PDF)

Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial

Vaccine, 2017-02, Vol.35 (6), p.923-928

2017

Volltextzugriff (PDF)

Randomized comparison of the safety of Flublok® versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥50 years of age

Vaccine, 2015-11, Vol.33 (48), p.6622-6628

2015

Volltextzugriff (PDF)

Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment-Experienced Subjects: 48-Week Results of the VICTOR-E1 Phase 2 Trial

The Journal of infectious diseases, 2010-02, Vol.201 (4), p.590-599

2010

Volltextzugriff (PDF)

Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5

Virology (New York, N.Y.), 2010-04, Vol.400 (1), p.145-155

2010

Volltextzugriff (PDF)

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

AIDS (London), 2007-06, Vol.21 (10), p.1293-1299

2007

Volltextzugriff (PDF)

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomized phase III trials

The Journal of infection, 2012-10, Vol.65 (4), p.326-335

2012

Volltextzugriff (PDF)

Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine

Clinical infectious diseases, 2024-07, Vol.79 (1), p.78-85

2024

Volltextzugriff (PDF)

COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials

Clinical infectious diseases, 2024-08, Vol.79 (2), p.364-374

2024

Volltextzugriff (PDF)

From down but Determined to Doctor: A Phenomenological View of Doctoral Students in an All-But-Dissertation Completion Program

Dunkle, Lisa A

2022

Volltextzugriff (PDF)

A Controlled Trial of Acyclovir for Chickenpox in Normal Children

The New England journal of medicine, 1991-11, Vol.325 (22), p.1539-1544

1991

Volltextzugriff (PDF)

Determination of Dosing Guidelines for Stavudine (2′,3′-Didehydro-3′-Deoxythymidine) in Children with Human Immunodeficiency Virus Infection

Antimicrobial Agents and Chemotherapy, 2001-03, Vol.45 (3), p.758-763

2001

Volltextzugriff (PDF)

1 – 25 von 110

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Englisch
(110)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(68)
Life Sciences & Biomedicine
(65)
Humans
(64)
Male
(38)
Female
(36)
Biological And Medical Sciences
(30)
Immunology
(29)
Medical Sciences
(26)
Adult
(25)
Pediatrics
(23)
Infectious Diseases
(22)
Child
(20)
Middle Aged
(19)
Adolescent
(18)
Aids/hiv
(18)
Child, Preschool
(18)
Infant
(16)
Pharmacology. Drug Treatments
(16)
Microbiology
(15)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE + GLA) adjuvant

Recombinant hemagglutinin influenza vaccine provides broader spectrum protection

NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial

Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults

Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18–49 Years of Age

Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized Trial

Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines

Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials

Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial

Randomized comparison of the safety of Flublok® versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥50 years of age

Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment-Experienced Subjects: 48-Week Results of the VICTOR-E1 Phase 2 Trial

Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomized phase III trials

Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine

COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials

Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials

From down but Determined to Doctor: A Phenomenological View of Doctoral Students in an All-But-Dissertation Completion Program

A Controlled Trial of Acyclovir for Chickenpox in Normal Children

Determination of Dosing Guidelines for Stavudine (2′,3′-Didehydro-3′-Deoxythymidine) in Children with Human Immunodeficiency Virus Infection

Suchergebnisse filtern